About the Authors

Thomas Prukop

Roles Conceptualization, Data curation, Writing – original draft

Affiliations Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany, University Medical Center Göttingen, Institute of Clinical Pharmacology, Göttingen, Germany

Jan Stenzel

Roles Data curation

Affiliation Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany

Stephanie Wernick

Roles Data curation

Affiliation Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany

Theresa Kungl

Roles Data curation

Affiliation Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany

Magdalena Mroczek

Roles Data curation

Affiliation Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany

Julia Adam

Roles Data curation

Affiliation Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany

David Ewers

Roles Data curation

Affiliation Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany

Serguei Nabirotchkin

Roles Conceptualization

Affiliation Pharnext, Issy-Les-Moulineaux, France

Klaus-Armin Nave

Roles Conceptualization, Writing – review & editing

Affiliation Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany

Rodolphe Hajj

Roles Conceptualization, Writing – review & editing

Affiliation Pharnext, Issy-Les-Moulineaux, France

Daniel Cohen

Roles Conceptualization, Writing – review & editing

Affiliation Pharnext, Issy-Les-Moulineaux, France

Michael W. Sereda

Roles Conceptualization, Writing – original draft

sereda@em.mpg.de

Affiliations Max-Planck-Institute of Experimental Medicine, Department of Neurogenetics, Göttingen, Germany, University Medical Center Göttingen, Department of Clinical Neurophysiology, Göttingen, Germany

Competing Interests

We have the following interests. This trial was financially supported by Pharnext, the employer of Serguei Nabirotchkin, Rodolphe Hajj and Daniel Cohen. DC, RH, MWS, TP and KAN submitted a patent based on this work: Full patent name: Early treatment of CMT disease Number: US2018/0000813. MWS, TP and KAN act as consultants to Pharnext. PXT3003 achieved a Phase 3 trial in CMT1A adult patients. There are no further patents related to this study, or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.